STAT+: Novartis’ biomedical research head on AI, pruning the pipeline, and a potential blockbuster
SAN DIEGO — For years, Novartis was known for advancing drugs based on their scientific odds of success, regardless of the size of the market awaiting those products. But the company is betting that, in […]
